Contents

Search

deuruxolitinib (Leqselvi)

Indications: - severe alopecia areata (FDA-approved 2024) * third JAK inhibitor FDA approved for severe alopecia areata Dosage: - 8 mg PO BID - tablets: 8 mg Adverse effects: - headache (12.4% vs 9.4% with placebo) - acne (10% vs 4.3% with placebo) - nasopharyngitis (8.1% vs 6.7% with placebo). Mechanism of action: - inhibits JAK1 & JAK2

Interactions

drug adverse effects of tyrosine kinase inhibitor(s)

General

small inhibitory antineoplastic agent (ib drug) Janus kinase inhibitor; JAK inhibitor

Database Correlations

PUBCHEM cid=72704611

References

  1. Brunk D FDA Approves JAK Inhibitor Deuruxolitinib for Alopecia Areata. https://www.medscape.com/viewarticle/fda-approves-jak-inhibitor-deuruxolitinib-alopecia-areata-2024a1000dsz